Journal of Clinical Trials
Open Access

Abstract

Resistance in Prostate Cancer: Mechanisms, Challenges and Therapeutic Innovations

Nidha Shapoo*, Naveed Shapoo, Noella Boma and Vladimir Gotlieb

Prostate cancer is the most frequently diagnosed malignancy and the second primary cause of cancer-related mortality among males in the United States and other Western nations. Androgen Deprivation Therapy (ADT) has served as the primary treatment for prostate cancer for several decades; however, the disease ultimately advances after a 2-3 years’ remission, resulting in Castration-Resistant Prostate Cancer (CRPC). Not withstanding progress in diagnostic techniques and therapeutic alternatives, resistance to treatment remains a considerable obstacle in disease management. This article examines the mechanisms of treatment resistance in prostate cancer and investigates different approaches to surmount these obstacles, including innovative treatment approaches as well as personalized medicine.

Published Date: 2024-12-20; Received Date: 2024-11-15